文献速递骨软组织肉瘤与黑色素瘤

伊匹木单抗联合抗PD-1免疫治疗的超急性毒性

Hyperacute toxicity with combination ipilimumab and anti-PD1 immunotherapy.
PubMed 文献 · Eur J Cancer · 2021-06-25

这项多中心回顾性研究分析了82例接受伊匹木单抗联合抗PD-1治疗的转移性黑色素瘤患者,发现9%出现超急性毒性(21天内≥2级irAE),中位发生时间10天。

要点

  • 联合免疫治疗超急性毒性发生率约9%,中位10天出现,可危及生命。
  • 免疫抑制强度越高PFS越差,但ORR和PFS与免疫抑制持续时间无关。

核心结论

  • 联合免疫治疗的超急性毒性谱广泛且可严重,许多患者需长期显著免疫抑制并仍面临后续严重毒性风险。
  • 此类患者黑色素瘤结局与试验人群相似,但免疫抑制需求增加可能与结局较差相关。

研究设计与样本

  • 多中心回顾性研究,从九个中心连续识别接受伊匹木单抗联合抗PD-1治疗后21天内发生≥2级irAE的转移性黑色素瘤患者。
  • 共82例患者发生超急性毒性,估计发生率9%。

主要发现

  • 超急性毒性中位发生时间10天(范围1-21天),毒性包括结肠炎23例、皮疹17例、肝炎9例、内分泌9例、肺炎6例、神经毒性4例。
  • 毒性分级为G2 38%、G3 52%、G4 6%、G5 2%(心肌炎)。
  • 29%发生额外超急性毒性,26%在治疗开始21天后但后续免疫治疗前发生另一毒性。
  • 客观缓解率54%,中位随访11.6个月后中位PFS 7.4个月。

临床怎么用

  • 联合免疫治疗开始后21天内需警惕超急性毒性,及时识别并处理≥2级irAE。
  • 超急性毒性常需显著免疫抑制且可能长期维持,应监测后续毒性风险。
  • 免疫抑制强度增加可能与PFS缩短相关,临床决策需权衡毒性管理与疗效。

局限性

  • 回顾性研究设计,样本量有限(82例),估计发生率基于九个中心数据。
  • 未随机分组,免疫抑制与结局的关联可能受混杂因素影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Combination ipilimumab and nivolumab is approved for several malignancies. Toxicity most often occurs 6-10 weeks into treatment. Whether very early toxicity is harder to manage or influences efficacy is unknown. METHODS: Consecutive metastatic melanoma patients who developed hyperacute toxicity, defined as Grade 2+ irAE within 21 days of receiving ipilimumab + anti-PD-1 were retrospectively identified from nine centres. RESULTS: A total of 82 patients developed hyperacute toxicity (estimated incidence 9%), at a median 10 days (range 1-21). Toxicities included colitis (N = 23), rash (17), hepatitis (9), endocrine (9), pneumonitis (6) and neurotoxicity (4) and were G2 (38%), G3 (52%), G4 (6%) and G5 (2% myocarditis). Fifty-nine percent required treatment beyond oral steroids, including IV steroids (28%), infliximab and other immunosuppression (30%). A total of 29% patients developed an additional hyperacute toxicity and 26% another toxicity >21 days after treatment commencement but before further immunotherapy. The objective response rate (ORR) was 54%, and after a median 11.6 mo follow-up, median PFS was 7.4 mo. Increasing levels of immunosuppression was associated with a reduced PFS (12-month PFS 62% no immunosuppression versus 49% oral steroids versus 33% IV steroids versus 20% further immunosuppressants, p = 0.006). There was no significant difference in ORR or PFS by duration of immunosuppression. CONCLUSIONS: Hyperacute toxicities from combination immunotherapy have a wide spectrum and can be severe. Many patients require significant immunosuppression for prolonged durations and remain at risk of further severe toxicity. Melanoma outcomes in such patients appear similar to those of trial populations, although greater immunosuppression requirements may be associated with inferior outcomes.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Dearden H, Au L, Wang DY, et al. Hyperacute toxicity with combination ipilimumab and anti-PD1 immunotherapy. Eur J Cancer. 2021. PMID: 34182268. doi:10.1016/j.ejca.2021.04.045

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。